You are here

Article Text

Article menu
Download PDFPDF
Letter to the Editor
Uveitis associated with OKT3 therapy for renal transplant rejection
  1. RAY F GARIANO,
  2. MARC L WEITZMAN
  1. Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, CT, USA
  1. Ray Gariano, MD, PhD, Yale University Eye Center, 330 Cedar Street, New Haven, CT 06520-8061, USA ray.gariano{at}yale.edu

https://doi.org/10.1136/bjo.85.4.496e

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Editor,—OKT3 (Ortho Biotech, Inc, Raritan, NJ, USA) is a murine monoclonal antibody to the CD3 receptor of human T lymphocytes, used in treatment of acute cellular graft rejection.1 Adverse effects of OKT3 include flu-like symptoms, hypotension, pulmonary oedema, cardiac dysfunction, aseptic meningitis, and visual complications.2 We describe uveitis following administration of OKT3.

    CASE REPORT

    A 51 year old man with polycystic renal disease underwent renal transplant from an unrelated donor. He was treated with antithymocyte globulin and steroid in the immediate postoperative period, and was discharged 7 days after surgery, with a nadir creatinine of 1.1, on cyclosporine 100 mg twice daily, prednisone 200 mg/day, amiodipine, nystatin, and famotidine.

    Creatinine rose to 1.9 on postoperative day 30, and renal biopsy demonstrated lymphocytic interstitial infiltration, tubulitis, and endothelialitis. …

    View Full Text